Enrollment completed in the MS-DETECT study

We are pleased to announce the completion of enrollment in MS-DETECT (NCT05816122), an international study supported by Sanofi.

This study evaluates MSCopilot® Detect, our digital medical device, designed to detect subtle signs of disability worsening related to multiple sclerosis (MS).

336 patients were enrolled across more than 35 centers in 7 countries: United States, Canada, France, Germany, Spain, Italy, and Denmark.

Initial results are expected in Q3 2027.

An initial presentation of interim data may be presented at ECTRIMS 2025.